Insulin detemir and insulin degludec represent two distinct approaches to basal insulin therapy. Detemir requires once- or twice-daily dosing due to its 16–24-hour duration, while degludec’s ultra-long half-life (>42 hours) enables true once-daily dosing with flexible timing — approaching weekly insulin pharmacokinetics. This comparison evaluates their suitability for weekly and flexible dosing strategies.
Detemir is a human insulin analog with ThrB30 deleted and a C-14 myristic acid chain acylated to LysB29. The fatty acid mediates reversible albumin binding, prolonging action beyond native insulin. However, the single fatty acid chain provides only moderate albumin association, limiting duration to approximately 16–24 hours.
Degludec replaces ThrB30 with a non-coded amino acid and attaches a C-16 hexadecanedioic acid via a γ-glutamic acid spacer to LysB29. The two-step mechanism — multi-hexamer chain formation followed by progressive albumin binding — produces a half-life exceeding 42 hours, more than double that of detemir.
| Parameter | Insulin Detemir | Insulin Degludec |
|---|
| Half-life | 5–7 hours | >42 hours |
| Duration of action | 16–24 hours | >42 hours |
| Minimum dosing frequency | Once daily (often twice) | Once daily |
| Flexible dosing | Limited (±2 hours) | Yes (±8 hours) |
| Missed dose buffer | 4–6 hours | >24 hours |
| Time to steady state | 2–3 days | 4–5 days |
| Weekly dosing feasibility | Not feasible | Approaches weekly pharmacokinetics |
Detemir requires consistent dosing intervals. Shifting injection times by more than 2–4 hours increases hypoglycemia risk. Degludec supports dosing interval shifts of up to 8 hours between consecutive days without increased hypoglycemia, a property unique among basal insulins.
| Dosing Scenario | Detemir Risk | Degludec Risk |
|---|
| Consistent daily timing | Low | Low |
| ±2 hours shift | Low | Low |
| ±4 hours shift | Moderate | Low |
| ±8 hours shift | High | Low |
| Missed dose (4 hrs late) | Moderate–high | Low |
| Missed dose (8 hrs late) | High | Low–moderate |
Detemir produces a relatively flat profile with a mild peak at 3–8 hours post-injection. The within-subject coefficient of variation (CV) is approximately 20–30%, necessitating consistent timing for predictable glucose lowering.
| PK Parameter | Detemir |
|---|
| Tmax | 3–8 hours |
| Half-life | 5–7 hours |
| Duration | 16–24 hours |
| CV (within-subject) | 20–30% |
| Steady state | 2–3 days |
Degludec produces an essentially peakless profile with ultra-low variability. The coefficient of variation is below 10% — the lowest among all basal insulins — providing consistent glucose lowering regardless of injection timing.
| PK Parameter | Degludec |
|---|
| Tmax | 9–12 hours |
| Half-life | >42 hours |
| Duration | >42 hours |
| CV (within-subject) | <10% |
| Steady state | 4–5 days |
| Parameter | Detemir | Degludec |
|---|
| HbA1c reduction | 1.0–1.5% | 1.0–1.5% |
| Fasting glucose reduction | 30–50 mg/dL | 30–50 mg/dL |
| Weight effect | Neutral to slight loss | Neutral |
| Parameter | Detemir | Degludec |
|---|
| Overall hypoglycemia | Moderate | Low |
| Nocturnal hypoglycemia | Moderate | Lowest among basal insulins |
| Confirmed hypoglycemia | Moderate | 30–40% lower than detemir |
Degludec’s ultra-flat pharmacokinetic profile translates to clinically meaningful reductions in hypoglycemia risk. The BEGIN and SWITCH trials demonstrated 30–36% reductions in nocturnal hypoglycemia compared to other basal insulins.
| Parameter | Detemir | Degludec |
|---|
| HbA1c with fixed timing | 1.0–1.5% | 1.0–1.5% |
| HbA1c with flexible timing | Not studied (not recommended) | 1.0–1.5% |
| Hypoglycemia with flexible timing | Increased | No increase |
| Step | Action | Rationale |
|---|
| 1 | Calculate total daily detemir dose | Baseline for conversion |
| 2 | Convert unit-for-unit | General recommendation |
| 3 | Reduce by 10–20% if high-dose | Degludec accumulates over 4–5 days |
| 4 | Administer degludec at consistent time for 5 days | Reach steady state |
| 5 | Resume flexible dosing after steady state | Maximize flexibility benefit |
| 6 | Titrate based on fasting glucose | Individualize |
| Detemir Dose | Degludec Starting Dose | Rationale |
|---|
| 10 U once daily | 10 U once daily | Unit-for-unit |
| 20 U once daily | 18 U once daily (10% reduction) | Accumulation buffer |
| 40 U once daily | 34 U once daily (15% reduction) | High-dose adjustment |
| 20 U twice daily (40 U total) | 36 U once daily (10% reduction) | Sum + adjustment |
| Clinical Scenario | Preferred Agent | Rationale |
|---|
| Need for flexible dosing | Degludec | ±8-hour window |
| Shift workers | Degludec | Flexible timing |
| Occasional missed doses | Degludec | Buffer effect |
| Travel across time zones | Degludec | Flexible timing |
| Cost sensitivity | Detemir | Generic available |
| Twice-daily basal required | Detemir | Shorter duration |
| Very low hypoglycemia risk needed | Degludec | Lowest CV |
| Needle phobia (pen device) | Degludec | Flextouch pen |
While neither detemir nor degludec is truly once-weekly, degludec’s pharmacokinetics approach weekly territory. The ultra-long half-life means that even with once-daily dosing, the drug level remains remarkably stable throughout the day and night. True once-weekly insulins (icodec, efsitora alfa) are in late-stage development, building on the albumin-binding and multi-hexamer concepts pioneered by detemir and degludec.
Detemir established the proof of concept for albumin-binding basal insulins but requires once- or twice-daily dosing with consistent timing. Degludec refined this approach with a longer fatty acid chain, spacer moiety, and multi-hexamer mechanism, achieving an ultra-long half-life that provides flexible once-daily dosing with no increased hypoglycemia risk. For patients requiring dosing flexibility, low hypoglycemia risk, or resistance to strict injection timing, degludec is the superior choice. Detemir remains relevant where cost or specific clinical circumstances favor its use.
